πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Iovance Biotherapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

Genelux Corporation

Genelux Corporation logo
Market Cap: Low
Employees: Lowest

Olvi-Vec

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for tough-to-treat cancers, with a lead product candidate, Olvi-Vec.

Tags: Olvi-Vec, biopharmaceutical, cancer treatment, clinical-stage, oncolytic viral immunotherapies

Symbol: GNLX

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Thomas Zindrick J.D.

Sector: Healthcare

Employees: 24

Address: 2625 Townsgate Road, Westlake Village, CA 91361

Phone: 858 483 0024

Leadership

  • Bob Smith, CTO
  • THOMAS ZINDRICK, J.D., Chairman
  • JAMES L. TYREE, MBA, Lead Independent Director
  • MARY MIRABELLI, MBA, Chair, Nominating and Corporate Governance Committee
  • JOHN THOMAS, M.A., MBA, Ph.D., Chair, Audit Committee
  • JOHN SMITHER, Chair, Compensation Committee
  • Alice Johnson, CEO
  • Carol Davis, CFO
  • David Wilson, Chairman
  • Eva Brown, Director

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. logo
Market Cap: Low
Employees: Low

LYL797, LYL845, NY-ESO-1

Lyell Immunopharma, Inc. is a biopharmaceutical company developing T cell therapies focused on treating patients with solid tumors using advanced genetic and epigenetic reprogramming technologies.

Tags: T cell therapy, biotechnology, cancer treatment, epigenetic reprogramming, genetic reprogramming, solid tumors

Symbol: LYEL

Recent Price: $0.62

Industry: Biotechnology

CEO: Dr. Lynn Seely M.D., Ph.D.

Sector: Healthcare

Employees: 224

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650 695 0677

Leadership

  • Lynn Seely, M.D., President & Chief Executive Officer
  • Stephen Hill, Chief Operating Officer
  • Matthew Lang, J.D., Chief Business Officer
  • Gary Lee, Ph.D., Chief Scientific Officer
  • Charles Newton, Chief Financial Officer
  • Ellen Rose, Senior Vice President, Investor Relations and Communications
  • Bryan Selby, Senior Vice President, Clinical Development Operations
  • Ann Tomlin, Senior Vice President, Human Resources
  • Rick Klausner, M.D., Founder & Board Chair
  • Crystal Mackall, M.D., Founder
  • Stan Riddell, M.D., Founder
  • Hans Bishop, Director
  • Otis Brawley, M.D., Director
  • Catherine Friedman, Director
  • Elizabeth Nabel, M.D., Director
  • Robert Nelsen, Director
  • William Rieflin, Director

Last updated: 2024-12-31

INmune Bio, Inc.

INmune Bio, Inc. logo
Market Cap: Low
Employees: Lowest

INKmune

INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.

Tags: Alzheimer's disease, chronic inflammation, hematologic malignancies, immunotherapy, solid tumors

Symbol: INMB

Recent Price: $4.65

Industry: Biotechnology

CEO: Dr. Raymond Joseph Tesi M.D.

Sector: Healthcare

Employees: 11

Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432

Phone: 858 964 3720

Last updated: 2024-12-31

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Immuno Phage platform

Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of immunotherapies for cancer, leveraging platforms such as Immuno Phage and Tumor Microenvironment Activated Biologics.

Tags: bacteriophage, biopharmaceutical, cancer treatment, immunotherapy, monoclonal antibodies

Symbol: SNSE

Recent Price: $0.48

Industry: Biotechnology

CEO: Mr. John K. Celebi M.B.A.

Sector: Healthcare

Employees: 28

Address: 451 D Street, Rockville, MD 02210

Phone: 240 243 8000

Last updated: 2024-12-31

AlloVir, Inc.

AlloVir, Inc. logo
Market Cap: Low
Employees: Lowest

posoleucel

Allovir, Inc. is a clinical-stage cell therapy company focused on the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat viral-associated diseases. It was founded in 2013 and is based in Waltham, Massachusetts.

Tags: VST therapies, biotechnology, cell therapy, clinical-stage, viral diseases

Symbol: ALVR

Recent Price: $0.45

Industry: Biotechnology

CEO: Dr. Diana M. Brainard M.D.

Sector: Healthcare

Employees: 8

Address: 1100 Winter Street, Waltham, MA 02451

Phone: 617 433 2605

Last updated: 2024-12-31

180 Life Sciences Corp.

180 Life Sciences Corp. logo
Market Cap: Lowest
Employees: Lowest

Therapeutics for chronic pain, inflammation, fibrosis, and inflammatory diseases

1180 Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis, using platforms such as fibrosis and anti-TNF, synthetic CBD analogs, and a7n ACh R.

Tags: CBD analogs, a7n ACh R, anti-TNF, biotechnology, chronic pain, clinical-stage, fibrosis, inflammation, therapeutics

Symbol: ATNF

Recent Price: $2.98

Industry: Biotechnology

CEO: Mr. Lloyd Blair Jordan L.L.B., M.B.A.

Sector: Healthcare

Employees: 4

Address: Building 4, Palo Alto, CA 94306

Phone: 650 507 0669

Last updated: 2024-11-08

BioVie Inc.

BioVie Inc. logo
Market Cap: Lowest
Employees: Lowest

BIV201, NE3107

Bio Vie Inc., a clinical stage biotechnology company, focuses on discovering, developing, and commercializing drug therapies in the United States, with products targeting liver cirrhosis, Alzheimer's, Parkinson's, multiple myeloma, and prostate cancer.

Tags: Alzheimer's, Biotechnology, Clinical Trials, Drug Development, Liver Cirrhosis, Parkinson's, Pharmaceutical

Symbol: BIVI

Recent Price: $2.09

Industry: Biotechnology

CEO: Mr. Cuong Viet Do M.B.A.

Sector: Healthcare

Employees: 14

Address: 680 West Nye Lane, Carson City, NV 89703

Phone: 775 888 3162

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Immunome, Inc.

Immunome, Inc. logo
Market Cap: Medium
Employees: Low

IMM-ONC-01, IMM-BCP-01

Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.

Tags: antibody therapeutics, biopharmaceutical, infectious disease, oncology

Symbol: IMNM

Recent Price: $10.28

Industry: Biotechnology

CEO: Dr. Clay B. Siegall Ph.D.

Sector: Healthcare

Employees: 78

Address: 665 Stockton Drive, Exton, PA 19341

Phone: 610 321 3700

Last updated: 2024-12-31

Immuneering Corporation

Immuneering Corporation logo
Market Cap: Lowest
Employees: Low

IMM-1-104 and IMM-6-415

Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.

Tags: biopharmaceutical, cancer treatment, drug development, neuroscience, oncology

Symbol: IMRX

Recent Price: $2.25

Industry: Biotechnology

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Employees: 66

Address: 245 Main Street, Cambridge, MA 02142

Phone: 617 500 8080

Last updated: 2024-12-31

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. logo
Market Cap: High
Employees: Medium

lifileucel

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to utilize the immune system in eradicating cancer cells, with several ongoing phase 2 clinical studies.

Tags: biotechnology, cancer immunotherapy, cancer treatment, clinical-stage, lifileucel

Symbol: IOVA

Recent Price: $7.17

Industry: Biotechnology

CEO: Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Sector: Healthcare

Employees: 557

Address: 825 Industrial Road, San Carlos, CA 94070

Phone: 650 260 7120

Last updated: 2024-12-31

Legend Biotech Corporation

Legend Biotech Corporation logo
Market Cap: Highest
Employees: High

LCAR-B38M

Legend Biotech Corporation is a clinical-stage biopharmaceutical company focusing on the discovery and development of novel cell therapies for oncology and other indications globally.

Tags: CAR-T, biopharmaceutical, cell therapy, clinical trials, lymphoma, multiple myeloma, oncology

Symbol: LEGN

Recent Price: $32.77

Industry: Biotechnology

CEO: Dr. Ying Huang Ph.D.

Sector: Healthcare

Employees: 2200

Address: 2101 Cottontail Lane, Somerset, NJ 08873

Phone: 732 317 5050

Leadership

  • Ying Huang, Ph.D., CHIEF EXECUTIVE OFFICER
  • Guowei Fang, Ph.D., CHIEF SCIENTIFIC OFFICER AND HEAD OF BUSINESS DEVELOPMENT
  • Lori Macomber, CHIEF FINANCIAL OFFICER
  • Mythili Koneru, M.D., Ph.D., CHIEF MEDICAL OFFICER
  • Jim Pepin, GENERAL COUNSEL
  • Steve Gavel, SENIOR VICE PRESIDENT, COMMERCIAL DEVELOPMENT, US & EUROPE
  • Yuhong Qiu, Ph.D., SENIOR VICE PRESIDENT, GLOBAL REGULATORY AFFAIRS
  • Birk VanderweeΓ«n, SENIOR VICE PRESIDENT, GLOBAL MANUFACTURING & SUPPLY
  • Alan Kick, SENIOR VICE PRESIDENT, GLOBAL QUALITY
  • Doug Wallace, VICE PRESIDENT, GLOBAL OPERATIONS
  • Elaine Qian, VICE PRESIDENT, GLOBAL HEAD OF HUMAN RESOURCES
  • Tim Roberts, Global Compliance Officer
  • Simon Wu, Senior Vice President, General Manager, Greater China
  • Frank Zhang, EMBA, Ph.D., CHAIRMAN OF THE BOARD, LEGEND BIOTECH
  • Sally Wang, M.S., PRESIDENT, GENSCRIPT
  • Zhu Li, Ph.D., CHIEF STRATEGY OFFICER, GENSCRIPT
  • Corazon (Corsee) Dating Sanders, Ph.D., CO-CHAIR OF THE BOARD OF ADVISORS, FRED HUTCH CANCER CENTER
  • Darren Ji, M.D., Ph.D. and MBA, CHAIRMAN AND CEO, ELPISCIENCE BIOPHARMACEUTICALS
  • Philip Yau, CHIEF FINANCIAL OFFICER. C&J CLARK
  • Patrick Casey, Ph.D., SENIOR VICE DEAN OF RESEARCH, DUKE-NUS MEDICAL SCHOOL SINGAPORE AND A JAMES B. DUKE PROFESSOR OF PHARMACOLOGY AND CANCER BIOLOGY, DUKE UNIVERSITY
  • Tomas J. Heyman, CEO, INTERLAKEN THERAPEUTICS
  • Li Mao, M.D., CHIEF MEDICAL OFFICER, SCICLONE PHARMACEUTICALS
  • Peter Salovey, Ph.D., Chris Argyris Professor of Psychology; Professor of Management, Epidemiology & Public Health, and Sociology; and President Emeritus of Yale University
  • Michel Vounatsos, FORMER CEO OF BIOGEN INC.
  • John Maraganore, Ph.D., FORMER CEO OF ALNYLAM PHARMACEUTICALS

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. logo
Market Cap: Lowest
Employees: Lowest

APVO436

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapeutic candidates to treat various forms of cancer, with a primary focus on APVO436, a bispecific T-cell engaging antibody for leukemia and myelodysplastic syndrome.

Tags: biotechnology, bispecific antibodies, cancer treatment, clinical-stage, immunotherapy

Symbol: APVO

Recent Price: $4.78

Industry: Biotechnology

CEO: Mr. Marvin L. White

Sector: Healthcare

Employees: 40

Address: 2401 4th Avenue, Seattle, WA 98121

Phone: 206 838 0500

Leadership

  • Marvin L. White, President and Chief Executive Officer
  • Jeff Lamothe, EVP and Chief Operating Officer
  • Daphne Taylor, SVP and Chief Financial Officer
  • Dirk Huebner, M.D., Chief Medical Officer
  • SoYoung Kwon, SVP, General Counsel, Business Development and Corporate Affairs

Last updated: 2024-12-31